Treatment of latent tuberculosis in liver transplant patients during their candidacy with INH or RIF appears to be a safe, viable option, if carefully monitored for adverse effects and liver enzymes.
No takes yet. Share an insight, caveat, or question.
Jahng et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: